Kelonia Therapeutics
Hsing-Chen Tsai, Ph.D., currently serves as Associate Director at Kelonia Therapeutics since October 2022, following a tenure as Senior Scientist and Senior Manager (Team Lead) at bluebird bio from 2018 to 2022, where leadership encompassed a gene therapy pipeline for ocular disease and hematopoietic stem cell programs for rare diseases. Prior experience includes roles as Scientist II at Alector, focused on antibody therapy for Alzheimer's Disease, and as a WRDM Postdoctoral Fellow at Pfizer, developing novel behavioral assays and an optogenetic platform for CNS disorders. Hsing-Chen Tsai's academic foundation includes a Ph.D. in Neurosciences from Stanford University and multiple degrees in molecular biology and epidemiology from Harvard University and Chang Gung University.
This person is not in any offices
Kelonia Therapeutics
1 followers
Kelona is revolutionizing gene delivery to expand the impact of genetic medicines. Their goal is to develop a new wave of accessible genetic medicines that will transform the lives of patients suffering from a broad range of conditions.